Arrayit Corporation (ARYC) leads and empowers the genetic, research, pharmaceutical, and diagnostic communities through the discovery, development and manufacture of proprietary life science technologies and consumables for disease prevention, treatment and cure. - Powerful Science for Life
Corporate - Media & Press – H1N1 Flu Pandemic Press Release
Arrayit Corporation Addresses Flu Pandemic
Breakthrough Technology Provides Population-Wide Screening
Source: Arrayit Corporation
On Thursday June 18, 2009, 7:00 am EDT
Arrayit Corporation (OTC.BB: ARYC), a leading manufacturer of products and services for disease prevention, treatment and cure, announced today that its microarray-based diagnostic test, patented under the trade name Variation Identification Platform (VIP), is ready for manufacture and distribution. A breakthrough screening test using VIP will allow clinicians and researchers to test and detect the H1N1 swine flu virus in population wide studies.
The World Health Organization (WHO) announced on June 11, that the threat level of the H1N1 swine flu virus is now a global pandemic. This news is ideally timed with Arrayit Corporation's release of its patented VIP screening test.
The Arrayit test will allow researchers and clinicians to detect the presence of the new H1N1 virus in mass numbers of flu patients, and to distinguish this threatening mutated strain from less harmful variants. Arrayit's first supplies will be sent to the Centers for Disease Control (CDC) in Atlanta to be approved for use in the USA. Shortly thereafter, the H1N1 test kits will be made available for emergency use by licensed clinics, laboratories and other health care organizations worldwide.
The VIP screening test is the first of its kind developed for multiple numbers of test subjects, with diagnosis available to patients within hours of testing. Up to 80,000 patients can be screened at a time, making it possible for entire communities and entire countries to quickly identify those infected with the new H1N1 virus. The ability to test and quickly diagnose mass numbers of subjects allows health clinicians the opportunity to gain control of the spread of the virus in a shorter time frame than current individual testing procedures. The VIP test kits will be made available at an affordable cost (estimated at under $50 per individual), making it feasible even for those without health insurance coverage to be screened.
About Arrayit Corporation
Arrayit Corporation, headquartered in Sunnyvale, California, leads and empowers the genetic, research, pharmaceutical, and diagnostic communities through the discovery, development and manufacture of proprietary life science technologies and consumables for disease prevention, treatment and cure. It now offers over 650 products to a customer base of more than 2,500 laboratories worldwide, including most every major university, pharmaceutical and biotech company, major agricultural and chemical company, government agency, national research foundation and many private sector enterprises. Please visit for more information.
Safe Harbor Statement
Except for historical information contained herein, statements made in this release that would constitute forward-looking statements may involve certain risks and uncertainties. All forward-looking statements made in this release are based on currently available information and the Company assumes no responsibility to update any such forward-looking statement. The following factors, among others, may cause actual results to differ materially from the results suggested in the forward-looking statements. The factors include, but are not limited to, risks that may result from changes in the Company's business operations; our ability to keep pace with technological advances; significant competition in the biomedical business; our relationships with key suppliers and customers; quality and consumer acceptance of newly introduced products; market volatility; non-availability of product; excess inventory; price and product competition; new product introductions, the outcome of our legal disputes; the possibility that the review of our prior filings by the SEC may result in changes to our financial statements; and the possibility that stockholders or regulatory authorities may initiate proceedings against Arrayit and/or our officers and directors as a result of any restatements. Risk factors associated with our business, including some of the facts set forth herein, are detailed in the Company's Form 10-K for the fiscal year ended December 31, 2008 and Form 10-Q/A for the fiscal first quarter ended March 31, 2008 and Form 10-Q for the fiscal third quarter ended September 30, 2008.
Copyright 1993-2019 Arrayit Corporation. All rights reserved.